Lakefront Biotherapeutics N.V. (LKFT) Stock Analysis & Investment Frameworks
Lakefront Biotherapeutics N.V. (LKFT) stock analysis on Invetso. Review Lakefront Biotherapeutics N.V.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Lakefront Biotherapeutics N.V. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: BE
Lakefront Biotherapeutics N.V. Key Financial Metrics
- Market Cap: $2.00B
- Revenue: $1.25B
- P/E Ratio: 5.55
- ROE: 16.88%
- ROIC: 11.61%
- Dividend Yield: N/A
About Lakefront Biotherapeutics N.V.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.